516 patents
Page 3 of 26
Utility
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
5 Sep 23
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
James D. Rodgers, Stacey Shepard
Filed: 8 Mar 22
Utility
Anti-mutant Calreticulin (Calr) Antibodies and Uses Thereof
31 Aug 23
Anti-mutant calreticulin (mutCALR) antibodies are disclosed.
Patrick Mayes, Horacio G. Nastri, Rebecca A. Buonpane, Edimara S. Reis, Shaun M. Stewart, Jing Zhou, Marc C. Deller, Hsiang-Ting Lei, Leslie Brooke Epling McQuirter, Yonghong Zhao, Hamza Celik, Brittney Melissa Wass
Filed: 7 Dec 22
Utility
Carboxamide compounds and uses thereof
22 Aug 23
Oleg Vechorkin, Jun Pan, Alexander Sokolsky, Evan Styduhar, Wenqing Yao
Filed: 9 Sep 20
Utility
ALK2 inhibitors for the treatment of anemia
15 Aug 23
Provided herein are methods of treating anemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an ALK2 inhibitor.
Francis Séguy, Ekaterine Asatiani, Yaoyu Chen
Filed: 15 Jun 21
Utility
Heterocyclic compounds as immunomodulators
8 Aug 23
Zhiyong Yu, Liangxing Wu, Wenqing Yao
Filed: 30 Dec 20
Utility
Tricyclic heterocyclic compounds as sting activators
1 Aug 23
The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
Filed: 2 Mar 21
Utility
Combination Therapy Comprising an FGFR Inhibitor and a Kras Inhibitor
20 Jul 23
The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.
Alejandro Amador Arjona, Angela Abdollahi, Margaret Favata, Jonathan Rios-Doria, Hui Wang, Susan Wee, Pei Gan, Jeffrey C. Yang, Yong Li, Le Zhao, Chunhong He, Chunyin Marshall Law, Wenyu Zhu, Xiaozhao Wang, Wenqing Yao, Peter Niels Carlsen, Fenglei Zhang, Qinda Ye, Matthew S. McCammant, Rocco Policarpo, Artem Shvartsbart, Jeremy Roach, Gia Hoang, Bin Hu, Gencheng Li, Robert Susick, Padmaja Polam, Chao Qi, Alexander Sokolsky, Haolin Yin, Chang Min
Filed: 21 Nov 22
Utility
Heterocyclic Compounds As Immunomodulators
20 Jul 23
Liangxing Wu, Ding-Quan Qian, Liang Lu, Neil Lajkiewicz, Leah C. Konkol, Zhenwu Li, Fenglei Zhang, Jingwei Li, Haisheng Wang, Meizhong Xu, Kaijiong Xiao, Wenqing Yao
Filed: 26 Sep 22
Utility
1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
18 Jul 23
The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
Filed: 4 Jun 21
Utility
Methods of Treating Cancer with an FGFR Inhibitor
13 Jul 23
This application relates to methods of treating cancer in a patient in need thereof, comprising administering a Fibroblast Growth Factor Receptors (FGFR) inhibitor to the patient.
Tao Ji, Krishnaswamy Yeleswaram
Filed: 3 Mar 23
Utility
Amorphous Solid Form of a Bet Protein Inhibitor
13 Jul 23
The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
Shili Chen, William Frietze, Zhongjiang Jia, Pingli Liu, Jiacheng Zhou
Filed: 31 Jan 23
Utility
Biomarkers for Vitiligo
13 Jul 23
Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor.
Michael D. Howell, Sherry Owens, Beth Rumberger, Huiqing Liu
Filed: 28 Dec 22
Utility
Naphthyridinone compounds as JAK2 V617F inhibitors
4 Jul 23
The present application provides naphthyridinone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Stacey Shepard, Lixin Shao, Liangxing Wu, Wenqing Yao
Filed: 17 Jun 21
Utility
Bicyclic Amine CDK12 Inhibitors
29 Jun 23
The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 12 (CDK12), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Xin Li, Michael Liang, Evan Styduhar, Robert Swyka, Oleg Vechorkin, Anlai Wang, Lin You, Peng Zhao, Ke Zhang, Minh Nguyen
Filed: 2 Dec 22
Utility
Processes of preparing a JAK1 inhibitor
27 Jun 23
The present application provides processes for preparing 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H, 1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, and phosphoric acid salt thereof, which is useful as a selective (Janus kinase 1) JAK1 inhibitor, as well as salt forms and intermediates related thereto.
Jiacheng Zhou, Yingrui Dai, Zhongjiang Jia, Yongchun Pan, James M. Parks, Anthony J. Tomaine, Jianji Wang, Aibin Zhang
Filed: 2 Jun 21
Utility
Tricyclic urea compounds as JAK2 V617F inhibitors
30 May 23
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Kai Liu, Brent Douty, Daniel Levy, Liangxing Wu, Wenqing Yao, Eddy W. Yue
Filed: 26 Aug 21
Utility
Multispecific Binding Moieties Comprising PD-1 and Tgf-brii Binding Domains
25 May 23
The present disclosure relates to a multispecific binding moiety comprising a PD-1 binding domain and a TGF-βRII binding domain, wherein the PD-1 binding domain blocks PD-1 mediated signaling and the TGF-βRII binding domain blocks TGF-βRII-mediated signaling.
Cecilia Anna Wilhelmina GEUIJEN, Patrick Mayes, Shaun M. Stewart, Liang-Chuan Wang
Filed: 18 Nov 22
Utility
Bipyrazole Derivatives As Jak Inhibitors
25 May 23
Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
Filed: 24 Jan 23
Utility
Treatment of Human Papillomavirus-associated Cancers by PD-L1 Inhibitors
18 May 23
The present disclosure relates to the treatment of HPV-associated cancers by small molecule PD-L1 inhibitors.
Ryan Geschwindt, Stephen Douglas Rubin
Filed: 23 Sep 22
Utility
Hetero-tricyclic Compounds As Inhibitors of Kras
18 May 23
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds.
Peter Carlsen, Ken Mukai, Haolin Yin, Xiaozhao Wang, Wenqing Yao, Wenyu Zhu
Filed: 20 Sep 22